Search bioRxiv⌕ Search

Biology subjects

Vlachou, D. F.

Publications and source records attributed to Vlachou, D. F..

2 recordsLinked to original sources

High-throughput platforms for genetic perturbation screening using CRISPR/Cas9 in human iPSC-derived macrophages for drug discovery

Human induced Pluripotent Stem Cell (hiPSC) models have revolutionised drug discovery, offering high translational relevance for recapitulating disease biology and thereby the potential to help reduce drug attrition. Macrophages are pivotal for maintaining tissue homeostasis and orchestrating immune responses; their dysregulation underpins several diseases, including autoinflammatory disorders, neurodegeneration, and cancer. Therapeutically targeting this cell type presents an attractive strategy to simultaneously influence multiple cellular mediators and functions. We have established a scalable, semi-automated, and physiologically relevant hiPSC-derived macrophage model, rigorously characterised through deep comparative multi-omics. We have also integrated our hiPSC-derived macrophage platform with large-scale CRISPR screening workflows designed for parallel genetic interrogation of thousands of gene targets, in both arrayed and pooled formats. In this manuscript, we apply those genetic screening methods to hiPSC-derived macrophages and showcase how genetic perturbations alter pro- and anti-inflammatory transcriptional signatures and significantly impact functional phenotypes in this cell model. This integrated approach allows for the exploration of novel genetic insights linked to causal disease biology, advancing myeloid cell-associated target discovery across a broad spectrum of therapeutic areas.

immunology↗

MALDI-TOF mass spectrometry and proteomics as phenotypic screening tools for anti-inflammatory drugs

Phenotypic screening is a powerful technology to discover drug candidates in physiologically relevant systems without prior knowledge of molecular targets; however, mass spectrometry (MS) remains underutilised as readout strategy. In this proof-of-concept study, we developed and evaluated two complementary MS-based phenotypic screening approaches to identify anti-inflammatory compounds in human induced pluripotent stem cell-derived macrophages and compared them to a conventional targeted cytokine profiling assay. First, we established a novel MALDI-TOF MS fingerprinting strategy that effectively distinguished macrophage phenotypes, identified phenotype-specific biomarkers, and maintained high-throughput capabilities while reducing cost. Secondly, we performed an in-depth LC-MS proteomic analysis using low cell input on an Evosep-timsTOF HT setup, providing rich molecular detail. Both MS-based approaches demonstrated large comparability with the cytokine assay, with a large proportion of hits overlapping. Notably, the proteomics workflow uniquely enabled deeper insight into inflammation pathway engagement, off-target effects, compound potency, and cytotoxicity. Together, these findings highlight the potential of MS-driven phenotypic screening to enhance early drug discovery by enabling efficient, informative, and cost-effective hit selection. O_FIG O_LINKSMALLFIG WIDTH=196 HEIGHT=200 SRC="FIGDIR/small/691706v1_ufig1.gif" ALT="Figure 1"> View larger version (59K): org.highwire.dtl.DTLVardef@c83cb7org.highwire.dtl.DTLVardef@a14d4org.highwire.dtl.DTLVardef@1dda6d7org.highwire.dtl.DTLVardef@f47564_HPS_FORMAT_FIGEXP M_FIG C_FIG

biochemistry↗